Patents by Inventor David Andrew Coates

David Andrew Coates has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • KRas G12C inhibitors
    Patent number: 10968214
    Abstract: The present invention provides compounds of the Formula I below where R1, R2 and m are as described herein, pharmaceutically acceptable salts of the compounds of Formula 1, and methods of using these compounds and salts for treating patients for cancer.
    Type: Grant
    Filed: October 8, 2019
    Date of Patent: April 6, 2021
    Assignee: Eli Lilly and Company
    Inventors: David Anthony Barda, David Andrew Coates, Ryan James Linder, Sheng-Bin Peng, Mohammad Sadegh Zia-Ebrahimi
  • Condensed thiophene derivatives useful as NaPi-IIb inhibitors
    Patent number: 10934280
    Abstract: The invention provides compounds of the formula: (A), pharmaceutically acceptable salts, pharmaceutical compositions thereof and methods of using these compounds, salts, or compositions to treat hyperphosphatemia, chronic kidney disease, and/or the cardiovascular disease associated with chronic kidney disease.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: March 2, 2021
    Assignee: Eli Lilly and Company
    Inventors: David Andrew Coates, Kevin Robert Fales, Jeffrey Allen Peterson, Jeffrey Michael Schkeryantz, Quanrong ' Shen, Matthew John Valli, John Rowley Wetterau, II, Dariusz Stanislaw Wodka, Yanping Xu
  • (E)-1-(4-(DIMETHYLAMINO)BUT-2-ENOYL)PYRROLIDIN-3-YL 4-((3-ISOPROPYL-5-METHYLPYRAZOLO[1,5-A]PYRIMIDIN-7-YL)AMINO)PIPERIDINE-1-CARBOXYLATE FOR INHIBITING CDK7
    Publication number: 20210032257
    Abstract: The present invention provides novel CDK7 inhibitors and pharmaceutical compositions thereof: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 22, 2020
    Publication date: February 4, 2021
    Inventors: David Andrew COATES, Carlos MONTERO, Bharvin Kumar Rameschandra PATEL, David Michael REMICK, Vipin YADAV
  • GLUCAGON-LIKE PEPTIDE1 RECEPTOR AGONISTS
    Publication number: 20200407347
    Abstract: In an embodiment, the present invention provides a compound of the formula: or a pharmaceutically acceptable salt thereof, and methods of using this compound for treating type II diabetes mellitus.
    Type: Application
    Filed: June 19, 2020
    Publication date: December 31, 2020
    Inventors: David Andrew COATES, Todd FIELDS, Joseph Daniel HO, Fucheng QU
  • DISUBSTITUTED PYRAZOLE COMPOUNDS
    Publication number: 20200392118
    Abstract: The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and non-alcoholic steatohepatitis.
    Type: Application
    Filed: June 16, 2020
    Publication date: December 17, 2020
    Inventors: David Andrew COATES, Timothy Barrett DURHAM, Richard Duane JOHNSTON, Steven Marc MASSEY, Patrick Gianpietro SPINAZZE, Douglas Richard STACK, James Lee TOTH
  • Amino pyrimidine ssao inhibitors
    Patent number: 10793552
    Abstract: The present invention provides compounds of the Formula (I), or a pharmaceutically acceptable salt thereof, where n and R1 are defined herein, methods of treating patients for liver disease, and processes for preparing the compounds.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: October 6, 2020
    Assignee: ELI LILLY AND COMPANY
    Inventors: David Andrew Coates, Luo Heng Qin, Yi Wei, Jingye Zhou
  • (E)-1-(4-(dimethylamino)but-2-enoyl)pyrrolidin-3-yl 4-((3-isopropyl-5-methylpyrazolo[1,5-a]pyrimidin-7-yl)amino)piperidine-1-carboxylate for inhibiting CDK7
    Patent number: 10787460
    Abstract: The present invention provides novel CDK7 inhibitors and pharmaceutical compositions thereof: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: September 29, 2020
    Assignee: Eli Lilly and Company
    Inventors: David Andrew Coates, Carlos Montero, Bharvin Kumar Rameschandra Patel, David Michael Remick, Yipin Yadav
  • AMINO PYRIMIDINE SSAO INHIBITORS
    Publication number: 20200262817
    Abstract: The present invention provides compounds of the Formula (I), or a pharmaceutically acceptable salt thereof, where n and R1 are defined herein, methods of treating patients for liver disease, and processes for preparing the compounds,
    Type: Application
    Filed: September 26, 2019
    Publication date: August 20, 2020
    Applicant: Eli Lilly and Company
    Inventors: David Andrew COATES, Luo Heng QIN, Yi WEI, Jingye ZHOU
  • CGRP RECEPTOR ANTAGONISTS
    Publication number: 20200181111
    Abstract: The present invention provides compounds of Formula II or a pharmaceutically acceptable salts thereof, useful as a CGRP receptor antagonist.
    Type: Application
    Filed: May 8, 2018
    Publication date: June 11, 2020
    Inventors: David Andrew Coates, Simon James Richards, Adam Jan Sanderson
  • KRAS G12C INHIBITORS
    Publication number: 20200115375
    Abstract: The present invention provides compounds of the Formula I below where R1, R2 and m are as described herein, pharmaceutically acceptable salts of the compounds of Formula 1, and methods of using these compounds and salts for treating patients for cancer.
    Type: Application
    Filed: October 8, 2019
    Publication date: April 16, 2020
    Inventors: David Anthony BARDA, David Andrew COATES, Ryan James LINDER, Sheng-Bin PENG, Mohammad Sadegh ZIA-EBRAHIMI
  • Dopamine D1 receptor positive allosteric modulators
    Patent number: 10611751
    Abstract: The invention provides certain (phenyl)-(pyrazol)-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one compounds of formula I as D1 positive allosteric modulators (PAMs), and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I, or a pharmaceutically acceptable salt thereof, to treat certain symptoms of Parkinson's disease, schizophrenia, ADHD or Alzheimer's disease.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: April 7, 2020
    Assignee: Eli Lilly and Company
    Inventors: Darryl Wayne Hilliard, Junliang Hao, David Andrew Coates
  • CONDENSED THIOPHENE DERIVATIVES USEFUL AS NAPI-IIB INHIBITORS
    Publication number: 20200031813
    Abstract: The invention provides compounds of the formula: (A), pharmaceutically acceptable salts, pharmaceutical compositions thereof and methods of using these compounds, salts, or compositions to treat hyperphosphatemia, chronic kidney disease, and/or the cardiovascular disease associated with chronic kidney disease.
    Type: Application
    Filed: August 8, 2017
    Publication date: January 30, 2020
    Inventors: David Andrew Coates, Kevin Robert Fales, Jeffrey Allen Peterson, Jeffrey Michael Schkeryantz, II, Quanrong ` Shen, Matthew John Valli, John Rowley Wetterau, II, Dariusz Stanislaw Wodka, Yanping Xu
  • (E)-1-(4-(DIMETHYLAMINO)BUT-2-ENOYL)PYRROLIDIN-3-YL 4-((3-ISOPROPYL-5-METHYLPYRAZOLO[1,5-A]PYRIMIDIN-7-YL)AMINO)PIPERIDINE-1-CARBOXYLATE FOR INHIBITING CDK7
    Publication number: 20200017513
    Abstract: The present invention provides novel CDK7 inhibitors and pharmaceutical compositions thereof: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 26, 2019
    Publication date: January 16, 2020
    Inventors: David Andrew COATES, Carlos MONTERO, Bharvin Kumar Rameschandra PATEL, David Michael REMICK, Yipin YADAV
  • Amino pyrimidine SSAO inhibitors
    Patent number: 10464928
    Abstract: The present invention provides compounds of the Formula (I), or a pharmaceutically acceptable salt thereof, where n and R1 are defined herein, methods of treating patients for liver disease, and processes for preparing the compounds.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: November 5, 2019
    Assignee: Eli Lilly and Company
    Inventors: David Andrew Coates, Luo Heng Qin, Yi Wei, Jingye Zhou
  • DOPAMINE D1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
    Publication number: 20190322639
    Abstract: The invention provides certain (phenyl)-(pyrazol)-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one compounds of formula I as D1 positive allosteric modulators (PAMs), and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I, or a pharmaceutically acceptable salt thereof, to treat certain symptoms of Parkinson's disease, schizophrenia, ADHD or Alzheimer's disease.
    Type: Application
    Filed: April 17, 2019
    Publication date: October 24, 2019
    Inventors: Darryl Wayne Hilliard, Junliang Hao, David Andrew Coates
  • ELECTROACOUSTIC DRIVER HOUSING ELEMENT
    Publication number: 20190327546
    Abstract: The present invention provides for a woven mesh element for an electroacoustic driver enclosure, and to an electroacoustic driver enclosure including such an element, wherein the element comprises a plurality of mesh layers, and wherein the said plurality of layers includes a layer of Dutch weave mesh preferably comprising a layer of Dutch Twill weave mesh, and in particular wherein the element comprises plural layers of cross woven wire mesh and a layer of Dutch weave wire mesh.
    Type: Application
    Filed: November 15, 2017
    Publication date: October 24, 2019
    Inventors: David Andrew Coates, John Robbert Kendrick
  • AMINO PYRIMIDINE SSAO INHIBITORS
    Publication number: 20190276436
    Abstract: The present invention provides compounds of the Formula (I), or a pharmaceutically acceptable salt thereof, where n and RI are defined herein, methods of treating patients for liver disease, and processes for preparing the compounds.
    Type: Application
    Filed: March 18, 2019
    Publication date: September 12, 2019
    Applicant: Eli Lilly and Company
    Inventors: David Andrew COATES, Luo Heng QIN, Yi WEI, Jingye ZHOU
  • ELECTROACOUSTIC DRIVER AND RELATED LOUDSPEAKER/SOUNDER
    Publication number: 20190268700
    Abstract: The present invention provides for an electroacoustic driver for use within an explosion proof loudspeaker or sounder and comprising a housing enclosing a coil of an electromagnet, the coil operatively coupled to an electromagnet core, a diaphragm located outside the housing for generating audible sound waves, a magnetic element located outside the housing and coupled to the diaphragm, wherein the electromagnet core extends through a wall of the housing from inside to outside of the housing to interact with the said magnetic element to cause movement of the diaphragm.
    Type: Application
    Filed: November 15, 2017
    Publication date: August 29, 2019
    Inventor: David Andrew Coates
  • Pyrazolylaminobenzimidazole derivatives as JAK inhibitors
    Patent number: 10323019
    Abstract: The present invention provides compounds of the formula below (I?): where R, and R1-R3 are as described herein, methods of treating patients for certain types of autoimmune diseases and cancer, and processes for preparing the compounds.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: June 18, 2019
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Joshua Ryan Clayton, David Andrew Coates, Daniel Jon Sall, Timothy Andrew Woods
  • PYRAZOLYLAMINOBENZIMIDAZOLE DERIVATIVES AS JAK INHIBITORS
    Publication number: 20190177300
    Abstract: The present invention provides compounds of the formula below (I?): where R, and R1-R3 are as described herein, methods of treating patients for certain types of autoimmune diseases and cancer, and processes for preparing the compounds.
    Type: Application
    Filed: February 12, 2019
    Publication date: June 13, 2019
    Inventors: Jolie Anne Bastian, Joshua Ryan Clayton, David Andrew Coates, Daniel Jon Sall, Timothy Andrew Woods